GRIGORIADIS, I.

Computer-aided drug design for conditional biomolecular interfaces requires evaluation across more than one receptor structure, docking pose, or scalar score. LINE-1 ORF1p is treated here as a state-family interface target whose relevant behavior is distributed across receptor microstates, assembly-compatible contact neighborhoods, ligand conformers, and perturbation snapshots. This article presents Linobectide as a mathematical-chemistry CADD workflow centered on a modified black-hole algorithm (MBHA) for persistence-weighted prioritization of putative ORF1p inhibitor candidates. Each molecule is represented as a dossier containing standardized descriptors, docking annotations, interaction-class persistence vectors, finite-action stability traces, graph-localization summaries, SPECTRAL-SAR applicability-domain records, and rank-shift diagnostics. The revised analysis emphasizes numerical reporting endpoints: fixed run parameters, baseline comparators, ablation metrics, rank stability, regeneration fractions, protected-elite fractions, and reproducibility indices. Docking is used as an annotation layer rather than as a stand-alone proof of inhibition. The framework is therefore reported as a transparent computational prioritization protocol that generates testable hypotheses for future biochemical and cellular validation, not as experimental proof of ORF1p inhibition or therapeutic activity.